Hydrochloric Acid → (2S)-2-methyl-1-[(6-methyl-3-pyridinyl)carbonyl]-4-{[2-methyl-4-(trifluoromethyl)phenyl]sulfonyl}piperazine hydrochloride
Reaction equation
Br[C:2]1[CH:7]=[C:6]([C:8]([F:11])([F:10])[F:9])[CH:5]=[CH:4][C:3]=1[S:12]([N:15]1[CH2:20][CH2:19][N:18]([C:21]([C:23]2[CH:24]=[N:25][C:26]([CH3:29])=[CH:27][CH:28]=2)=[O:22])[C@@H:17]([CH3:30])[CH2:16]1)(=[O:14])=[O:13].[C:31](=O)([O-])[O-].[K+].[K+].CB1OB(C)OB(C)O1.[ClH:46]>O1CCOCC1.C(Cl)Cl.CCOCC.C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1>[ClH:46].[CH3:30][C@H:17]1[CH2:16][N:15]([S:12]([C:3]2[CH:4]=[CH:5][C:6]([C:8]([F:11])([F:10])[F:9])=[CH:7][C:2]=2[CH3:31])(=[O:14])=[O:13])[CH2:20][CH2:19][N:18]1[C:21]([C:23]1[CH:24]=[N:25][C:26]([CH3:29])=[CH:27][CH:28]=1)=[O:22]Participants
Reactant 4
Product 1
Reagents, catalysts & solvents 4
Conditions
- Temperature
- 100 °C
Procedure
(2S)-4-{[2-bromo-4-(trifluoromethyl)phenyl]sulfonyl}-2-methyl-1-[(6-methyl-3-pyridinyl)carbonyl]piperazine (may be prepared as described in Description 31) (216 mg, 0.427 mmol), potassium carbonate (153 mg, 1.109 mmol) in 1,4-dioxane (9 ml) were stirred for 5 min then trimethylboroxin (0.154 ml, 1.109 mmol) and Pd(PPh3)4 (84 mg, 0.073 mmol) were added and the reaction mixture heated at 100° C. for 1 h. The reaction mixture was concentrated under vacuum, dissolved in MeOH and filtered through a 5 g SCX column. LCMS showed still some triphenylphosphine oxide and another small impurity so the product was dissolved in EtOAc (40 ml) and extracted with HCl 2N (40 ml). 2 N NaOH was added to the aqueous layer until pH12 and product extracted with EtOAc (100 ml). The organic phase was dried on a phase separation cartridge and concentrated under vacuum. LCMS of the first EtOAc layer showed it contained some of the product so was extracted again with 2 N HCl (40 ml). 2 N NaOH was added to the aqueous layer until pH12 and product extracted with EtOAc (100 ml). The organic layer was dried on a phase separation cartridge and the two batches were combined and concentrated under vacuum to give the free base of the product. The product was suspended in DCM, 0.5 ml of 1 N HCl in ether was added and the solvent was evaporated to give the title compound (193 mg).
Workup
- concentrationThe reaction mixture was concentrated under vacuum
- dissolutiondissolved in MeOH
- filtrationfiltered through a 5 g SCX column
- dissolutionanother small impurity so the product was dissolved in EtOAc (40 ml)
- extractionextracted with HCl 2N (40 ml)
- addition2 N NaOH was added to the aqueous layer until pH12 and product
- extractionextracted with EtOAc (100 ml)
- customThe organic phase was dried on a phase separation cartridge
- concentrationconcentrated under vacuum
- extractionso was extracted again with 2 N HCl (40 ml)
- addition2 N NaOH was added to the aqueous layer until pH12 and product
- extractionextracted with EtOAc (100 ml)
- customThe organic layer was dried on a phase separation cartridge
- concentrationconcentrated under vacuum
- customto give the free base of the product
- customthe solvent was evaporated
Sources & evidence
- ORD record
- ord-1d969a86e9b844ca9ad021a4421df82b
- Source dataset
- uspto-grants-2012_10
- Patent number
- US08288388B2
Reaction notes
Loading…